Christine PooleThermo Fisher ScientificTMOTOP PICKJun 13, 2023

He bought this in mid-2023 on a dip. It's been consolidating the healthcare space for the last 10 years. Are #1 in this space. He expects sales and their PE to improve.

She bought in summer, stock's not done too much, so it gets to be a Top Pick again. Vast array of picks and shovels to the healthcare industry. Reduced guidance a couple of times, very unusual for them: weakness in China, general caution in spending, and Covid-double-ordered inventory destocking. Likes long-term fundamentals of healthcare industry, and TMO will participate. Yield is 0.3%.

Is up 11% in the past month. Their customers have finished clearing out their excess inventory after a year. Better US-China relations means more sales for TMO.

TMO is a leader in life sciences and diagnostics. He recently added. The entire sector has some over-supply. This is the bottom of the cycle. Lower risk, less upside, more diversified. Historically, good at acquisitions. Good long-term hold, but right now it's all about waiting for funding to come back to the sector.

When the cycle turns, both will do well and will probably outperform.

It is the leading global player in life sciences and tools. It provides drug companies, pharmaceuticals and labs and in fact is vital to the pharmaceutical industry in helping with drug development. The overhang is weakness in China and bio-tech companies but this should be a temporary headwind. With a good management team it is growing in the U.S. with several acquisitions. The pull back makes it a good time to buy for the long term.       Buy 21  Hold 6  Sell 1

Spend the last ~20 years consolidating scientific/diagnostics tools market.
Very strong demand for health care products.
Strong pipeline of R&D.
Expecting a 5-7% revenue growth & double digit earnings growth.
Great compounding business for long term shareholder.

Leader in technology in sectors that are solid but not hot. Largest player in devices needed for research. Successfully integrates acquisitions. Pick and shovels. Revenue growth of 8-10%. Not cheap, but foresees 10-15% growth per annum for 5-6 years. Yield is 0.26%.

Healthcare products and services. Benefitted from Covid, and financial windfall can be used to reinvest in the business. Growth will be flat this year and then pick up. Raised growth target to 7-9% annually on topline. 82% of revenue is recurring, a defensive characteristic. Yield is 0.26%. 

Leading health care providers to pharma companies.
Excellent at M&A the past 10 years.
Large R&D pipeline.
Also good in hardware sales for new drugs.
Benefited from Covid-19 pandemic.
Recent share price weakness presenting good buying opportunity.
Expecting growth of revenue and earnings. 

October-November marked a major low. Range-bound between $600-520. As long as it doesn't take out the $520 level to the downside, doesn't mind nibbling here for the longer term. He expects we're starting a new 4-year cycle for a 3-5 year bull market. See his Top Picks.

It has differing moving parts and has a growth component - lab samples go to their products associated with lab work. Personalized medicine is a major growth area and means more specific types of testing. This will benefit TMO

Great company over the long term.
Weak share price a good time to invest.
Grow company that has volatility.
M&A strategy will be good if assets remain cheap.

A great company, a mid-tech conglomerate that aggressively buys companies and boasts recurring revenues. We're approaching a recession, but buy for the long-term and buy in tranches.

Currently owns shares in the company.
Share price presenting good value.
Wonderful long term performer.
Highly specialized equipment that is in high demand.
Recurring revenue model with requirement to service machines.
Company investing in new products and services with strong cash flow.